Concern
40 plain-language articles on longevity & aging — the physiology, the compounds researched for it, and what the evidence actually shows.
40 articles
AMPK — the cellular energy sensor and why metformin became a longevity drug
Metformin has been prescribed to people with type 2 diabetes since the 1950s in Europe and since 1995 in the United States. It is among the most prescribed drugs in the world, with a safety profile that decades of clinical use have established as genuinely good. For most of that time, nobody fully understood how it worked. The pharmacological mechanism — what it was actually doing in the cell to lower blood glucose — was the subject of debate for more than forty years. The explanation, when it arrived in the early 2000s, turned out to be more interesting than a diabetes mechanism. It pointed at a kinase that sits at the center of cellular energy sensing, and through that kinase it connected metformin to a biology that reaches from mitochondria to mTOR to lifespan.
Autophagy — the cellular cleanup system that aging depends on
Yoshinori Ohsumi's laboratory in Tokyo was not working on aging. In the early 1990s, he was a cell biologist studying vacuoles — the storage compartments of yeast cells — using a relatively simple experimental approach: starve the yeast, then look at the vacuoles under a microscope and see what happens. What happened, in cells he had genetically engineered to prevent the breakdown of what accumulated there, was that the vacuoles filled with tiny spherical structures. The structures were coming from the cytoplasm. The cell was packaging pieces of itself and delivering them to the vacuole for digestion. Ohsumi had found, and then systematically characterized, the genetic machinery underlying a process that had been glimpsed in electron micrographs since the 1960s but had never been cracked at the molecular level. He called it autophagy — from the Greek for self-eating — and in 2016 he received the Nobel Prize in Physiology or Medicine for the discovery that this cellular self-digestion was not aberrant but exquisitely regulated, essential for survival under stress, and implicated in diseases from cancer to neurodegeneration to aging itself.
The Bryan Johnson "Don't Die" phenomenon — what the protocol actually does and what it doesn't
In February 2023, a photograph of Bryan Johnson standing shirtless next to his 17-year-old son and his 70-year-old father circulated widely across social media. The premise was that Johnson, then 45, had biomarker readings suggesting his biological age was younger than his chronological age — and the photograph was offered as evidence of some kind of metabolic convergence across three generations. People reacted the way people react when something is simultaneously compelling and uncomfortable: they shared it while expressing ambivalence about whether they were supposed to find it inspiring or disturbing. Both responses were tracking something real.
Cardiogen — the cardiac peptide bioregulator
A cardiologist sees the numbers and tells you they're fine. Blood pressure 128/82 — a little elevated but not worth treating yet. Ejection fraction normal. Resting heart rate slightly elevated, maybe. No blockages on the scan. And yet you're 58 years old and you wake up at 2 a.m. with a heaviness in your chest that is almost certainly anxiety and you can't quite shake the sense that something in the machinery is running harder than it should to produce the same output it produced ten years ago. Your tolerance for exertion has changed in ways you've explained to yourself as deconditioning or stress. The fatigue after a difficult week has a different quality than it used to — slower to resolve, sitting deeper. Nothing wrong. Nothing actionable. The space between "healthy" and "diagnosed" is where most people live for most of their lives, and in cardiovascular terms, it's a long space.
Cellular senescence in deeper detail — the biology, biomarkers, and intervention frontier
A cell under severe stress faces a choice. It can repair the damage and carry on. It can trigger apoptosis — the orderly self-destruction program that eliminates compromised cells cleanly. Or it can do something else: it can stop dividing, enlarge, change its behavior, and stay. This third option is cellular senescence, and for decades it was understood primarily as a tumor suppression mechanism — a way of permanently halting cells that might otherwise accumulate mutations and turn cancerous. That understanding was correct as far as it went. What took longer to recognize was the cost.
The David Sinclair NAD+ story — hype, evidence, honest assessment
In the late 1990s, a graduate student named David Sinclair was working in Lenny Guarente's lab at MIT, trying to understand why yeast cells age. The answer his experiments pointed toward involved a protein called Sir2 — Silent Information Regulator 2. In yeast, Sir2 controlled whether certain genomic regions were transcriptionally active or silenced, and its activity appeared to be linked to lifespan. When you increased Sir2 expression in yeast, the cells lived longer. When you inhibited it, they lived less long. Sinclair went on to characterize Sir2 and its mammalian cousins, the sirtuins, as what he would eventually describe as a master regulatory system of aging — a set of molecular sensors that respond to cellular stress and energy status and govern whether cells survive, repair themselves, or succumb to aging-associated dysfunction.
Epigenetic clocks — Horvath, GrimAge, and what biological age tests actually measure
You spit in a tube, seal it, mail it off, and eight weeks later a number arrives: your biological age. Maybe the report says 38.2. You're 44 chronologically. A minor celebration. Or it says 47.6, and you spend the next week wondering what exactly you've been doing to yourself. The number has a quality of authority that a cholesterol panel carries — it arrives formatted, annotated, compared to a reference range, delivered by a company with a clean website and peer-reviewed citations in the footer. The question worth asking before you do anything with it is what the number actually measures, how confident you should be in it, and what the science behind it can and cannot honestly tell you.
Epitalon and the Khavinson school — the deeper Russian research history
In the mid-1970s, in Leningrad — not yet St. Petersburg again — a Soviet military physician named Vladimir Khavinson began a research program that would eventually span five decades and produce a body of work that most Western scientists have never read. The institutional home was the Military Medical Academy, a prestigious institution with origins dating to the eighteenth century, where Khavinson was working in the department of pathophysiology. The question he was pursuing was not fashionable by Western standards: it was whether the aging process could be slowed through targeted peptide administration. Not reversed, not indefinitely extended — slowed. The Soviet framing of the problem was practical, almost industrial. What compounds could preserve the functional capacity of soldiers, cosmonauts, and aging populations? The research that followed was shaped by that institutional context.
Epitalon and the telomere conversation — what Khavinson's research actually showed
In the 1970s, Soviet medicine was running a parallel research program that Western researchers mostly couldn't read. Not because it was hidden — it was published, regularly, in Soviet and Russian journals — but because the language barrier was real, the institutional infrastructure for translation was limited, and the scientific exchange between Soviet and Western research communities was episodic at best. One of the things being published in that parallel program was a body of work on peptide bioregulators: short peptides derived from organ tissues that appeared, in the laboratory and in animal studies, to exert regulatory effects on specific biological systems. The researcher at the center of this work was Vladimir Khavinson, working at the Institute of Bioregulation and Gerontology in St. Petersburg — the institution that would, decades later, produce the compound that sparked a still-ongoing conversation in longevity biology.
N-Acetyl Epithalon Amidate vs Epitalon — why the modification matters
You've looked into Epitalon. You've read about Khavinson's research, the telomerase hypothesis, the Russian clinical tradition. And then, browsing sources and supplier listings, you encounter a different name: N-Acetyl Epithalon Amidate. Or Epithalon Amidate. Or Acetyl Epitalon. The naming is inconsistent in the way that peptide supplement markets tend to be. What isn't inconsistent is the underlying question: is this the same compound, a better version, or something different enough to matter?
Exosomes and extracellular vesicles — the cell-to-cell communication system you didn't learn about
In 1983, two separate research groups — one in Montreal, one in Boston — were studying how developing red blood cells dispose of their transferrin receptors as they mature. The cell needed to get rid of certain surface proteins. They watched it do something unexpected: instead of simply degrading the receptors, the cell packaged them into tiny membrane-bound bubbles and released them into the surrounding fluid. The bubbles were assumed to be waste. Cellular garbage bags. The researchers noted the finding, named the vesicles, and moved on. Nobody thought this was a communication system. Nobody thought it was going to matter.
FOXO transcription factors — the longevity nodes you didn't learn about
In 1993, a graduate student named Cynthia Kenyon made a worm live twice as long. The organism was Caenorhabditis elegans, the one-millimeter nematode that had become molecular biology's favorite model because its entire nervous system — 302 neurons — is mapped, its genome is sequenced, and its lifespan, normally around three weeks, is short enough to run multiple generations of aging experiments in a semester. Kenyon's lab found that a single mutation in a gene called daf-2 doubled the worm's lifespan. Not extended it modestly. Doubled it. The worm also remained healthier for longer — more active, more stress-resistant, physiologically younger at the midpoint of its extended life than normal worms were at their natural endpoint. The finding was so extreme that the field initially questioned whether it was real.
FOXO4-DRI — the senolytic peptide that started the conversation
In the spring of 2017, a paper appeared in the journal Cell that produced an unusual reaction in the longevity research community — a reaction that was part scientific excitement, part careful skepticism, and part something rarer in academic biology: the sense that a mechanism had been found that was genuinely elegant. The paper came from Peter de Keizer and colleagues at Erasmus University Medical Center in Rotterdam. The compound at the center of it was a synthetic peptide called FOXO4-DRI. The images that accompanied the paper — aged mice that had regrown their fur, restored their kidney function, run faster, recovered what looked like younger vitality after treatment — circulated widely online in a way that peer-reviewed biology papers almost never do.
GDF11 and GDF15 — the controversial aging factors discovered in young blood
The experiment looked like science fiction when it first appeared in the literature, though the technique was nearly a century old. Parabiosis — surgically joining two animals so that they share a circulatory system — had been used intermittently since the 1950s to study blood-borne factors. What Tom Rando's lab at Stanford and Amy Wagers's lab at Harvard were doing in the mid-2000s was pairing old mice with young ones and asking what happened. What happened was striking. Old mice connected to young circulatory systems showed improvements in muscle regeneration, liver function, and in some paradigms, brain physiology. Young mice connected to old circulatory systems showed the reverse — accelerated deterioration of some measures. The implication was immediate and difficult to dismiss: something in the blood of young animals was promoting tissue maintenance, and something in the blood of old animals was impairing it. The factors responsible were unknown. Finding them became one of the more intensely pursued objectives in aging biology.
Gene expression and tissue specificity — why the same genome makes different cells
In 1962, a British developmental biologist named John Gurdon did something that shouldn't have been possible according to the consensus of the day. He took the nucleus of a fully differentiated intestinal cell from an adult frog, transplanted it into an enucleated frog egg, and watched it develop into a functioning tadpole. The experiment was technically difficult, widely doubted, and conceptually unsettling, because it implied something that the field hadn't fully accepted: differentiated cells don't lose genetic information when they specialize. The intestinal cell's nucleus contained everything needed to build a complete organism. Every cell type, throughout the frog's body, carried the full complement of genetic instructions. They just used different parts of it.
The Hayflick limit and telomerase — why cells stop dividing, and why that's complicated
In the late 1950s, the prevailing belief among cell biologists was that cells grown in culture were, in principle, immortal. The authority for that view was Alexis Carrel, a Nobel laureate who claimed to have kept a culture of chick heart cells dividing continuously for decades — long past the lifespan of any chicken. The conclusion drawn from Carrel's famous experiment was that cells did not age; only the organism did, and any limit on a cell's lifespan in a dish must be a failure of technique. Then a young anatomist named Leonard Hayflick, working at the Wistar Institute in Philadelphia, started paying close attention to his own cultures of human fibroblasts and noticed something Carrel's dogma did not predict. The cells divided vigorously, then slowed, then stopped. Every time. No matter how perfect the culture conditions.
Healthy aging in the 70s and 80s — what the peptide conversation looks like at this stage
You are seventy-five and you are, by most measures, doing well. You walk every morning. You see your grandchildren. Your last labs were good enough that your doctor barely discussed them. You're on a statin that you've been taking for twelve years and an antihypertensive that you adjusted to about three years ago, and maybe a low-dose aspirin that your cardiologist still recommends even though the guidelines have shifted. You've read something about peptides and longevity. Your son or daughter has mentioned them. And you want to understand whether any of this is relevant to you and your situation.
Insulin signaling and aging — from C. elegans to human metabolic disease
In 1993, a developmental biologist at the University of California San Francisco named Cynthia Kenyon made an observation that should have seemed impossible. She mutated a single gene in a millimeter-long nematode worm called Caenorhabditis elegans, a creature with a normal lifespan of roughly three weeks, and the worm lived twice as long. Not marginally longer. Twice as long. The gene was daf-2, the worm's equivalent of the insulin and IGF-1 receptor, and the mutation reduced its activity. The worm didn't just survive longer — it remained active and youthful longer, compressing its period of deterioration rather than extending it. Kenyon later described the moment as the discovery that aging was subject to genetic regulation, not merely the inevitable accumulation of wear. The implication was enormous: if a single signaling pathway could gate the lifespan of an organism, then aging was not a passive process. It was regulated. And what is regulated can, in principle, be intervened upon.
Altered intercellular communication — how the body's cells stop talking clearly
In 1956, a Cornell researcher named Clive McCay did something that sounds more like gothic fiction than gerontology: he surgically joined the bodies of an old rat and a young rat so that they shared a single bloodstream. Skin was sutured to skin, the two circulatory systems grew together, and for weeks the pair lived as one fused organism. When McCay examined the old animals afterward, their bones looked younger and denser than those of age-matched rats that had not been joined. The technique was called parabiosis, and the result hinted at something strange and important — that whatever ages a body is carried, at least in part, in the blood, and that the blood of the young carries something else. The experiment was crude, the animals suffered, and the field largely set it aside for half a century. Then, in the 2000s, it came roaring back.
Klotho — the longevity protein and the cognitive aging connection
The mouse looked old at three months. Not sickly in the way of a diseased animal — old, in the way of an animal whose systems had outpaced their design envelope. Muscle wasting. Skin atrophy. Vascular calcification. Emphysema-like lung changes. Hearing loss. Infertility. Osteoporosis. Cognitive decline. Death, typically before the animal reached two months of age when the phenotype was fully penetrant. Makoto Kuro-o, working at the National Institute of Neuroscience in Tokyo in 1997, had been doing conventional insertional mutagenesis screens — randomly disrupting genes in mice to see what happened — when he produced a mouse that had accidentally become a model of premature aging. He named the disrupted gene after the Greek Fate who spins the thread of life: Klotho.
Livagen — chromatin stabilization and DNA repair in the bioregulator framework
The laboratory image is precise and strange: a short chain of four amino acids, smaller than most molecules a pharmacologist would bother with, threading itself into the major groove of a DNA double helix. Not acting on a cell surface receptor. Not blocking an enzyme. Sitting inside the chromatin structure, interacting directly with the DNA-protein complex that governs which genes are expressed and which are silenced. This is the mechanism the Khavinson laboratory proposed for its short peptide bioregulators — and Livagen, a tetrapeptide sequence, is among the clearest examples of how that mechanism was understood to work and why it generated both genuine scientific interest and deep skepticism from Western researchers who encountered it.
MicroRNAs — the tiny regulators of aging biology
In 1993, a graduate student at Harvard named Rosalind Lee was studying a mutant strain of the nematode worm Caenorhabditis elegans that had been puzzling researchers for years. The worm had a defect in timing — its larval cells kept cycling as if they didn't know what developmental stage they were in. The responsible gene, lin-4, had been mapped but didn't code for any protein. That was the strange part. Most of molecular biology at the time assumed that if a gene mattered, it made a protein. Lin-4 didn't. What Lee and her mentor Victor Ambros found instead was that lin-4 produced a tiny RNA molecule — only twenty-two nucleotides long — that bound to the messenger RNA of another gene called lin-14 and suppressed its translation. The gene was writing instructions in RNA that silenced other instructions. It was regulation all the way down, and in a form nobody had been looking for.
The mTOR / autophagy axis — what it is and what peptides nudge it
In 1964, a Canadian research expedition to Easter Island — Rapa Nui in the Polynesian language — collected soil samples from the island's volcanic terrain with no particular expectation of what they'd find. Years later, a microbiologist named Suren Sehgal working at Ayerst Pharmaceuticals discovered in those samples a bacterium, Streptomyces hygroscopicus, that produced an unusual compound with antifungal activity. He named the compound rapamycin, after the island. Sehgal kept the project alive through corporate reorganizations, famously storing vials of rapamycin in his own home freezer when the program was nearly shut down. His instinct that the molecule was important proved correct, though neither he nor anyone else in 1972 fully understood why.
NAD+ vs NMN vs NR — the precursor conversation
You're standing in the supplement aisle — or the online equivalent of it, scrolling through a longevity stack that someone recommended on a podcast — and there are three things that look related: NAD+, NMN, and NR. They're all described as "NAD+ support." They're all priced somewhere between expensive and extremely expensive. They're all backed by citations to researchers whose names you half-recognize. And the differences between them are explained, in every product description you've read, in a way that somehow makes it less clear what you should actually be taking, not more.
Nutrient sensing — the four pathways that decide between growth and longevity
In the early 1990s, on the remote Pacific island of Rapa Nui — Easter Island — researchers studying a soil bacterium called Streptomyces hygroscopicus isolated a compound the bacterium used to suppress competing fungi. They named it after the island: rapamycin. For years it was developed as an antifungal, then as an immunosuppressant to prevent organ-transplant rejection. Only later, when biologists traced exactly how it worked, did they find that rapamycin acts on a single protein so central to how cells decide whether to grow that they named the protein after the drug: the mechanistic target of rapamycin, mTOR. That a fungus-fighting molecule from an island soil bacterium turned out to be a key that fits one of the master switches of cellular aging is one of the stranger origin stories in biology — and it opens directly onto the question of how cells know whether it is time to grow or time to endure.
Peptide stacks for longevity vs performance — different goals, different combinations
You're 48. You train four days a week, you sleep reasonably well, your labs are broadly fine, and you've been reading about peptides for six months. You have a list of compounds and no coherent framework for how they fit together. Someone told you BPC-157 was good. Someone else said Epitalon was what you actually needed. A forum thread convinced you that Ipamorelin plus CJC-1295 was the move, but then another thread contradicted it with an argument about IGF-1 and cancer risk that you haven't been able to shake. The problem isn't information. You have too much information. The problem is a framework for understanding what you're actually trying to do.
Peptides after 50 — the integrated landscape across systems
You used to be able to push through it. A bad week of sleep, a hard training block, a stretch of stress — you absorbed it, and the recovery came. Not anymore, or not the same way. The lag is longer. The baseline you return to is a little lower each time. The things that were always true about your body feel less reliable, and the list of adjustments you've made — earlier bedtime, less alcohol, more careful with the knees — is longer than it was five years ago, and you keep adding to it.
Peptides for longevity and aging — what research has explored across the hallmarks of aging
You notice it not as a single event but as an accumulation of small ones. The recovery after a hard workout takes two days instead of one. The cut on your hand heals, but slower than you remember. The focus that used to arrive automatically needs to be summoned. None of these changes are dramatic enough to take to a doctor. Cumulatively, they sketch something you recognize and don't want to name.
Peptides for vision protection — glaucoma, macular degeneration, and dry eye
You find out you have glaucoma at a routine eye exam. Nothing hurt. Nothing looked different. The visual field test catches a small defect at the periphery, the pressure reading is elevated, the optic nerve has a cup-to-disc ratio that concerns your optometrist enough to send you to an ophthalmologist. The diagnosis is startling not because of what it has done yet but because of what it might do, silently, if the pressure isn't controlled — and because the vision that glaucoma takes doesn't come back. You were not expecting this conversation at 52.
Peptides in frailty — what the geriatric medicine evidence suggests
You're watching your father lose weight he wasn't trying to lose. He gets tired walking to the mailbox, something that wasn't true eighteen months ago. He moves more carefully now, and the carefulness has a different quality than before — less deliberate, more uncertain. His grip strength is down. He's had one fall. His doctor says he's in the frailty range and talks about nutrition and maybe physical therapy. You've been reading about peptides and wondering if any of it applies to him.
Peptides vs rapamycin for longevity — the decision framework
You're trying to decide where to start. You've read enough to know that the longevity pharmacology space has more than one lane, that something called rapamycin exists and appears in research conversations with unusual frequency, and that peptides occupy a different part of the landscape. What you haven't found is a direct comparison that treats both honestly — where the evidence is strong, where it's speculative, and how to think about the choice rather than just hand you a preference.
Proteostasis — the quality-control network that keeps proteins from killing cells
A protein begins life as a featureless string. The ribosome reads the genetic code and links amino acids one by one into a linear chain, and that chain, in itself, does nothing — it is a sentence with no meaning until it folds. Folding is where a protein becomes a machine: the chain collapses, in milliseconds to seconds, into a precise three-dimensional shape, and that shape is the function. An enzyme's pocket that grips its target, an antibody's arms that clamp an antigen, the channel in a membrane protein that lets ions through — all of it is folded geometry. Christian Anfinsen won a Nobel Prize for showing, in the 1960s, that a protein's sequence contains the instructions for its own folded shape. But Anfinsen worked with purified proteins in a test tube. Inside a living cell, folding has to happen in a chaotic, crowded environment, at speed, on tens of thousands of different proteins at once, with new chains pouring off ribosomes every second and old proteins constantly being damaged. The fact that this works at all, reliably, for decades, is one of the quiet miracles of cellular life, and the system that makes it work is called proteostasis.
The senescent cell story — what makes cells 'zombie cells'
You cut your hand and it heals. The skin closes, the inflammation resolves, the scar fades over months. At no point do you consciously manage this — your body runs an intricate repair sequence without your input, and if you're young and healthy, the outcome is essentially complete restoration. What you don't see is the cellular machinery underneath that sequence: cells dividing to replace damaged ones, immune cells clearing debris, signaling molecules coordinating the whole operation with timing measured in hours. And somewhere in that process, certain cells that have served their purpose — that have divided as many times as they safely can, or that have accumulated damage that makes further division risky — enter a state from which they will not emerge. They stop dividing and stay stopped. They are still alive. They will not come back.
Senolytics in plain English — clearing aged cells as an aging strategy
You're sixty-two and your joints ache in ways they didn't at fifty. Not an injury — nothing you can point to. Just a general, ambient stiffness that is worst in the morning and never quite goes away. Your doctor says it's wear and tear, which is medically accurate and explains nothing. What it doesn't explain is the mechanism underneath — why tissues that were working fine for decades are now failing in a way that feels less like breakdown and more like something actively going wrong.
Sirtuins — the longevity proteins and what they actually do
In the late 1990s, a yeast cell in Leonard Guarente's lab at MIT quietly upended the assumption that lifespan was a fixed parameter. The gene in question was Sir2 — Silent Information Regulator 2 — and when researchers added extra copies of it to yeast, the cells lived longer. When they deleted it, the cells died sooner. Nobody had expected a single gene to move the lifespan needle in either direction. The question the experiment opened wasn't just "what does Sir2 do" but something more unsettling: if a gene could regulate how long a cell lives, what exactly is the machinery of aging, and how close to the surface is it?
Stem cell exhaustion — why the body's repair reserve runs down
In 1961, two researchers at the Ontario Cancer Institute, Ernest McCulloch and James Till, were trying to measure radiation sensitivity in mouse bone marrow. They injected marrow cells into irradiated mice and noticed something they had not been looking for: lumps growing on the spleens of the recipients, one lump for roughly every so many cells injected. Each lump turned out to be a colony of blood cells, and each colony, they eventually proved, had grown from a single cell that could both copy itself and produce every type of blood cell. They had stumbled onto the first quantitative proof that stem cells exist. The discovery reframed how biologists thought about tissue: a body is not a fixed set of cells that you are issued at birth and slowly lose, but a system continually rebuilt from small reserves of cells held back for exactly that purpose.
Telomere biology and aging — what Elizabeth Blackburn's discovery means for you
In 2009, Elizabeth Blackburn, Carol Greider, and Jack Szostak shared the Nobel Prize in Physiology or Medicine for their discovery of how chromosomes are protected by telomeres and the enzyme telomerase. The prize validated decades of work that had started in an unlikely place: the single-celled pond organism Tetrahymena, which Blackburn and Szostak used to identify the repetitive DNA sequences capping chromosome ends, and which Blackburn and Greider then used to discover the enzyme responsible for maintaining them. The Nobel committee was recognizing work that had already reshaped cell biology. What they were also recognizing, by extension, was a molecular framework for understanding one of the most important questions in aging research: why do cells stop dividing?
Feeling like you're aging faster than your peers
There was a reunion — or a photo, or a run into someone from a former chapter of your life — and the comparison was unavoidable. They looked the same. Roughly the same as a decade ago, the same as your memory of them. You looked at yourself in the same context and recognized that you don't. The skin has changed more. The hair is thinner, or grayer, or both. The body composition has shifted in ways that feel less like normal variation and more like drift in a direction you didn't choose. It might have been a single photo. It might be a persistent, private sense that the gap between your chronological age and how you look and feel is not running in your favor.
The unfolded protein response — how the cell handles its own folding crises
In the late 1980s, a cell biologist named Mary-Jane Gething and her colleague Joe Sambrook were studying how a viral protein folds inside cells when they noticed something that did not fit. When they forced cells to accumulate a misfolded protein in a compartment called the endoplasmic reticulum, the cells responded by ramping up production of a particular set of helper proteins — as if the cell had detected the folding problem and was calling for reinforcements. The cell, in other words, was monitoring the quality of its own protein folding and reacting when that quality slipped. Over the following decade, laboratories led by researchers including Peter Walter and Kazutoshi Mori would work out the machinery behind that reaction and give it a name: the unfolded protein response. It turned out to be one of the most important quality-control systems a cell possesses, and its failure runs through some of the most feared diseases in medicine.
Vesugen — the vascular endothelium bioregulator
Arterial stiffness doesn't announce itself the way a heart attack does. It accumulates across years — a gradual loss of compliance in vessel walls that used to spring back, a creeping rise in systolic blood pressure that your doctor notes but doesn't yet treat, a resting heart rate that has ticked up slightly without obvious cause. Your arteries at 50 behave differently than they did at 30, and not in ways that show up on a single test. They show up in the aggregate of things that are harder to measure: exercise tolerance that has plateaked, recovery from exertion that takes longer, blood pressure that runs higher on difficult weeks than it used to. None of this is a diagnosis. All of it is real.